Shrewsbury and Telford Hospital NHS Trust has begun enrolling pregnant volunteers in BEATRIX, described by researchers as the first large-scale phase-three trial of a vaccine meant to stop Group B streptococcus infecting newborns.

Why GBS matters in maternity units

Group B strep colonises many women without symptoms yet can trigger sepsis, pneumonia or meningitis in babies within hours of birth. Antibiotics during labour reduce risk when clinicians know a mother carries the bacteria, but screening gaps and rapid-onset disease still drive neonatal intensive care admissions across the NHS.

Professor William Parry-Smith, consultant obstetrician and Keele University academic, leads the site as principal investigator. The trial is sponsored by Pfizer and supported by the National Institute for Health and Care Research, reflecting a push to move maternal immunisation from RSV and pertussis successes into bacterial threats.

How participation works

Pregnant participants join for about fourteen months, with infant follow-up for a year after delivery. Visits track immune responses, safety signals and pregnancy outcomes against placebo. Eligibility screens mirror standard NHS antenatal care; women already under Shrewsbury consultants receive information packs through midwifery teams rather than cold calls.

Investigators stress that the product remains investigational: it is not available on prescription, and declining trial entry does not affect routine maternity care. Labour wards continue existing antibiotic protocols regardless of trial status.

Broader NHS context

If BEATRIX succeeds, the Joint Committee on Vaccination and Immunisation would still need to review cost-effectiveness before any routine programme. Similar pathways followed respiratory syncytial virus immunisation for infants. For now, Shropshire families willing to volunteer provide data that could change global stillbirth and neonatal death statistics modellers cite in the tens of thousands per year.

Hospitals in other UK regions are expected to open sites as recruitment ramps this autumn. InfoHandle will track JCVI commentary once interim readouts appear.

Trial ethics committees reviewed consent materials to ensure pregnant volunteers understand placebo risk and visit burdens. Partners are encouraged to attend information evenings at the trust's women's centre. Data will feed a global database comparing immunogenicity across sites in Europe and North America as Pfizer expands recruitment.

Midwives at the trust received refresher training on trial eligibility screens so routine antenatal visits can offer participation without delaying scans.

Local editors will refresh quotes and confirmed figures after primary sources publish final readouts later in the day, avoiding speculation on numbers still moving in live markets or matches.

Shropshire maternity capacity

The trust's neonatal unit coordinates with regional transport teams if trial participants deliver early, ensuring ambulances are briefed on study IDs without delaying emergency care. Paediatricians not involved in BEATRIX remain responsible for treatment decisions independent of trial assignment.

Public health directors in the West Midlands have promoted antenatal messaging about GBS screening limits, explaining that maternal vaccination research complements but does not replace existing antibiotic protocols during labour.